BIOMAT Database Logo BIOMAT Database Logo

Woodfruticosin (woodfordin C), a new inhibitor of DNA topoisomerase II. Experimental antitumor activity. 1992

A Kuramochi-Motegi, and H Kuramochi, and F Kobayashi, and H Ekimoto, and K Takahashi, and S Kadota, and Y Takamori, and T Kikuchi
Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co., Tokyo, Japan.

Woodfruticosin (woodfordin C) (WFC), a new inhibitor of DNA topoisomerase II (topo-II), was isolated from methanol extract of Woodfordia fruticosa Kurz (Lythraceae) and studied for in vitro and in vivo antitumor activities in comparison with Adriamycin (ADR) and etoposide (ETP), well known inhibitors of topo-II. The inhibitory activity against DNA topo-II shown by WFC was much stronger than that shown by ETP or ADR. WFC inhibited strongly intracellular DNA synthesis but not RNA and protein synthesis. On the other hand, WFC had a weaker growth inhibitory activity against various human tumor cells than ETP or ADR, but it showed remarkable activity against PC-1 cells and moderate activity against MKN45 and KB cells. Furthermore, WFC had in vivo growth inhibitory activity against s.c. inoculated colon38. These results indicate that the mechanism by which WFC exhibits antitumor activity may be through inhibition of topo-II.

UI MeSH Term Description Entries
D007941 Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene. P388D(1) Leukemia,P388, Leukemia
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000972 Antineoplastic Agents, Phytogenic Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. Antineoplastics, Botanical,Antineoplastics, Phytogenic,Agents, Phytogenic Antineoplastic,Botanical Antineoplastics,Phytogenic Antineoplastic Agents,Phytogenic Antineoplastics
D013634 Tannins Polyphenolic compounds with molecular weights of around 500-3000 daltons and containing enough hydroxyl groups (1-2 per 100 MW) for effective cross linking of other compounds (ASTRINGENTS). The two main types are HYDROLYZABLE TANNINS and CONDENSED TANNINS. Historically, the term has applied to many compounds and plant extracts able to render skin COLLAGEN impervious to degradation. The word tannin derives from the Celtic word for OAK TREE which was used for leather processing. Tannin
D016923 Cell Death The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability. Death, Cell

Related Publications

A Kuramochi-Motegi, and H Kuramochi, and F Kobayashi, and H Ekimoto, and K Takahashi, and S Kadota, and Y Takamori, and T Kikuchi
Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.
January 2002, Molecular cancer therapeutics,
A Kuramochi-Motegi, and H Kuramochi, and F Kobayashi, and H Ekimoto, and K Takahashi, and S Kadota, and Y Takamori, and T Kikuchi
Saintopin, a new antitumor antibiotic with topoisomerase II dependent DNA cleavage activity, from Paecilomyces.
October 1990, The Journal of antibiotics,
A Kuramochi-Motegi, and H Kuramochi, and F Kobayashi, and H Ekimoto, and K Takahashi, and S Kadota, and Y Takamori, and T Kikuchi
UCT4B, a new antitumor antibiotic with topoisomerase II mediated DNA cleavage activity. Structure determination.
February 1993, The Journal of antibiotics,
A Kuramochi-Motegi, and H Kuramochi, and F Kobayashi, and H Ekimoto, and K Takahashi, and S Kadota, and Y Takamori, and T Kikuchi
UCT4B, a new antitumor antibiotic with topoisomerase II mediated DNA cleavage activity, from Streptomyces sp.
July 1992, The Journal of antibiotics,
A Kuramochi-Motegi, and H Kuramochi, and F Kobayashi, and H Ekimoto, and K Takahashi, and S Kadota, and Y Takamori, and T Kikuchi
Antitumor quinolones with mammalian topoisomerase II mediated DNA cleavage activity.
May 1992, Cancer research,
A Kuramochi-Motegi, and H Kuramochi, and F Kobayashi, and H Ekimoto, and K Takahashi, and S Kadota, and Y Takamori, and T Kikuchi
UCT1072s, new antitumor antibiotics with topoisomerase II mediated DNA cleavage activity, from Aspergillus sp.
November 1999, The Journal of antibiotics,
A Kuramochi-Motegi, and H Kuramochi, and F Kobayashi, and H Ekimoto, and K Takahashi, and S Kadota, and Y Takamori, and T Kikuchi
DA-125, a new antitumor agent, inhibits topoisomerase II as topoisomerase poison and DNA intercalator simultaneously.
January 2004, Archives of pharmacal research,
A Kuramochi-Motegi, and H Kuramochi, and F Kobayashi, and H Ekimoto, and K Takahashi, and S Kadota, and Y Takamori, and T Kikuchi
Syntheses of novel antitumor dihydroxanthone derivatives with inhibitory activity against DNA topoisomerase II.
September 1999, Bioorganic & medicinal chemistry letters,
A Kuramochi-Motegi, and H Kuramochi, and F Kobayashi, and H Ekimoto, and K Takahashi, and S Kadota, and Y Takamori, and T Kikuchi
S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition.
February 1998, Molecular pharmacology,
A Kuramochi-Motegi, and H Kuramochi, and F Kobayashi, and H Ekimoto, and K Takahashi, and S Kadota, and Y Takamori, and T Kikuchi
DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy.
April 1990, BioEssays : news and reviews in molecular, cellular and developmental biology,
Copied contents to your clipboard!